Allos' Efaproxyn falls short in cancer trial
Allos Therapeutics, a Colorado, USA-based drugmaker, says that a combination of Efaproxyn (efaproxial), its developmental hypoxic sensitizer, and whole brain radiation therapy, failed to bring about a statistically significant improvement in overall survival, compared with WBRT alone, in women suffering from brain metastases as a result of advanced breast cancer.
The Phase III ENRICH study showed that overall survival in patients who received Efaproxyn plus WBRT was, according to a stratified log rank analysis, 8.5 months, compared with 7.5 months in the group treated with WBRT. The drug also failed to achieve any of its secondary endpoints. Allos said that, based on these findings, it has discontinued development of the drug, and is instead focusing its R&D efforts on its investigational lymphoma therapy PDX (pralatrexate), which is currently in Phase II trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze